Heartwire
Hot Line I – Insuffisance cardiaque et dysfonction
ventriculaire gauche
Dimanche 29 août, 11 h 00 – 12 h
Stockholm – Zone K
ventriculaire gauche
Dimanche 29 août, 11 h 00 – 12 h
Stockholm – Zone K
Télécharger le PDF  |
The STAR heart study: The acute and long-term effect of intracoronary stem-cell transplantation in 191
patients with chronic heart failure Dimanche 29 août, 11 h 00 – 11 h 13 Bodo E Strauer, Heinrich Heine University, Düsseldorf, Allemagne |
| PEARL HF: Multicenter, randomized, double-blind, placebo-controlled, parallel-group, multiple-dose study to
evaluate the effects of RLY5016 in heart failure patients Dimanche 29 août, 11 h 18 – 11 h 31 Bertram Pitt, University of Michigan, Ann Arbor, MI, É.-U. |
|
| SHIFT: Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart
failure and left ventricular systolic dysfunction Dimanche 29 août, 11 h 36 – 11 h 49 Michel Komajda, Université Pierre et Marie Curie, Paris, France |
|
| ALPHA OMEGA: Effect of low doses of n-3 fatty acids on cardiovascular diseases in post-MI patients Dimanche 29 août, 11 h 54 – 12 h 0 Daan Kromhout, Université de Wageningen, Pays-Bas |
|
| HEBE III: A single dose of erythropoietin in ST-elevation myocardial infarction Dimanche 29 août, 12 h 12 – 12 h 25 Adrian A Voors, University Medical Center Groningen, Pays-Bas |
Hot Line II – Maladie coronaire
Lundi 30 août, 11 h 00 – 12 h 30
Stockholm – Zone K
Lundi 30 août, 11 h 00 – 12 h 30
Stockholm – Zone K
|
INNOVATE PCI: A phase II safety and efficacy study of PRT060128 (elinogrel), a novel intravenous and oral
P2Y12 inhibitor, in non-urgent PCI (INNOVATE-PCI) Lundi 30 août, 11 h 00 – 11 h 10 Sunil Rao, Duke University Medical Center, Durham, NC, É.-U. |
| ART: A randomised trial to compare survival following bilateral versus single internal mammary (IMA) grafting
in coronary revascularization Lundi 30 août, 11 h 15 – 11 h 25 David P Taggart, John Radcliffe Hospital, Oxford, G.-B. |
|
| Long-term comparison of everolimus-eluting and sirolimus-eluting stents for coronary revascularization Lundi 30 août, 11 h 30 – 11 h 40 Stephan Windecker, Hôpital universitaire, Bern, Suisse |
|
| ATOLL: An international, randomized trial comparing IV enoxaparin with IV unfractionated heparin in primary
PCI for ST-elevation myocardial infarction Lundi 30 août, 11 h 45 – 11 h 55 Gilles Montalescot, Hôpital La Pitié-Salpêtrière, Paris, France |
|
| ISAR REACT 3A: A trial of reduced dose of unfractionated heparin in patients undergoing percutaneous
coronary interventions Lundi 30 août, 12 h 00 – 12 h 10 Stefanie Schulz, Deutsches Herzzentrum, Munich, Allemagne |
|
| Double-blind, placebo-controlled phase II studies of E5555 in Japanese patients with acute coronary
syndrome (ACS) and coronary artery disease (CAD) Lundi 30 août, 12 h 15 – 12 h 25 Shinya Goto, Tokai University, Isehara, Japon |
Hot Line III – Maladie cardiovasculaire et troubles du rythme
Mardi 31 août, 11 h 00 – 12 h 30
Stockholm – Zone K
Mardi 31 août, 11 h 00 – 12 h 30
Stockholm – Zone K
|
DANPACE: The Danish multicenter randomised trial on single lead atrial versus dual chamber pacing in sick
sinus syndrome Mardi 31 août, 11 h 00 – 11 h 10 Jens C Nielsen, Aarhus University Hospital, Aarhus N, Danemark |
| RESPONSE: Effect of a nurse coordinated prevention program on cardiovascular risk after an acute coronary
syndrome: Main results of the RESPONSE trial Mardi 31 août, 11 h 15 – 11 h 25 Ron J Peters, Université d’Amsterdam, Pays-Bas |
|
| AVERROES: Apixaban versus acetylsalicylic acid (ASA) to prevent strokes Mardi 31 août, 11 h 30 – 11 h 40 Stuart J Connolly, McMaster University, Hamilton, ON, Canada |
|
| EINSTEIN DVT: Oral rivaroxaban versus standard therapy in the initial treatment of symptomatic deep vein
thrombosis and long-term prevention of recurrent venous thromboembolism Mardi 31 août, 11 h 45 – 11 h 55 Harry Buller, Academic Medical Center, Amsterdam, Pays-Bas |
|
| ANTIPAF: Angiotensin II-antagonist in paroxysmal atrial fibrillation trial Mardi 31 août, 12 h 00 – 12 h 10 Andreas Goette, Otto-von-Guericke-University Hospital, Magdeburg, Allemagne |
|
| FUTURA OASIS 8: A randomised trial comparing two regimens of adjunctive intravenous unfractionated
heparin during PCI in high-risk patients with non-STE-ACS treated with fondaparinux Mardi 31 août, 12 h 15 – 12 h 25 Sanjit Jolly, McMaster University, Hamilton, ON, Canada |
